A Clinical Trial of MK-1167 in Healthy Adults (MK-1167-010)

NCT07266818 | Active Not Recruiting Phase 1 FDA Drug

• 1 other identifier: 1167-010
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this trial is to learn about the safety of MK-1167 and if people tolerate it.

Conditions

Healthy

Outcome Measures

Primary Outcomes (2)

• Number of Participants Who Experience an Adverse Event (AE)

  An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

  Up to approximately 9 weeks

• Number of Participants Who Discontinue Study Treatment Due to an AE

  An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.

  Up to approximately 1 week

Study Arms (2)

MK-1167

EXPERIMENTAL

MK-1167 administered orally

Drug: MK-1167

Placebo

PLACEBO COMPARATOR

Placebo for MK-1167 administered orally

Drug: Placebo

Interventions

MK-1167 DRUG

Oral capsule administered once daily

MK-1167

Placebo DRUG

Oral capsule administered once daily

Placebo

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Is in good health
• Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2, inclusive
• Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases
• Is a smoker and/or has used nicotine or nicotine-containing products (for example, nicotine patch and electronic cigarette) within the past 3 months

Sponsors & Collaborators

• Merck Sharp & Dohme LLC: lead

Study Sites (1)

Hassman Research Institute Marlton Site ( Site 0001)

Marlton, New Jersey, 08053, United States

Location

Related Links

• Merck Clinical Trials Information

Study Officials

• Medical Director

  Merck Sharp & Dohme LLC

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 1, 2025
• First Posted: December 5, 2025
• Study Start: December 18, 2025
• Primary Completion: April 13, 2026
• Study Completion: April 13, 2026
• Last Updated: April 13, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will share

Locations

US (1)